Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)

PURPOSE: We conducted a phase I study to determine the maximum tolerated dose and recommended dose (RD) of this gemcitabine plus cisplatin (GC) combination in the adjuvant setting for biliary tract cancer (BTC). GC has become a standard chemotherapy regimen for patients with locally advanced or meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyoda, Masanori, Ajiki, Tetsuo, Fujiwara, Yutaka, Nagano, Hiroaki, Kobayashi, Shogo, Sakai, Daisuke, Hatano, Etsuro, Kanai, Masashi, Nakamori, Shoji, Miyamoto, Atsushi, Tsuji, Akihito, Kaihara, Satoshi, Ikoma, Hisashi, Takemura, Shigekazu, Toyokawa, Hideyoshi, Terajima, Hiroaki, Morita, Satoshi, Ioka, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032637/
https://www.ncbi.nlm.nih.gov/pubmed/24614947
http://dx.doi.org/10.1007/s00280-014-2431-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032637/
https://www.ncbi.nlm.nih.gov/pubmed/24614947
http://dx.doi.org/10.1007/s00280-014-2431-y

Ejemplares similares